Researchers from Erasmus University Medical Center and the University of Missouri have developed an optical imaging probe that can identify microscopic cancer cells in the margins of tumour-resected cavities in the brain. The probe works by exploiting the increased fatty acid metabolism exhibited by glioblastoma cells and has shown promising results in preclinical studies. This breakthrough could lead to more accurate removal of glioblastoma during surgery and potentially delay cancer recurrence.
Forecast for 6 months: The developed optical imaging probe is expected to undergo further testing and refinement in the next 6 months, with potential clinical trials planned for the second half of the year.
Forecast for 1 year: By the end of the year, the optical imaging probe is expected to be approved for use in clinical trials, paving the way for its potential adoption in brain cancer surgery.
Forecast for 5 years: Within the next 5 years, the optical imaging probe is expected to become a standard tool in brain cancer surgery, leading to improved patient outcomes and potentially delaying cancer recurrence.
Forecast for 10 years: By the end of the decade, the optical imaging probe is expected to be widely adopted in brain cancer treatment, leading to significant improvements in patient survival rates and quality of life.
